BIOGEN U.S. CORPORATION
- CAMBRIDGE, MA 02142-1031
- Corporate Entity (Not Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $206.5K
- Awards on record
- 8
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
BIOGEN U.S. CORPORATION has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About BIOGEN U.S. CORPORATION
- Headquarters
- CAMBRIDGE, MA 02142-1031
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIE82LHNZSCUA3
- CAGE6M2Q6
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $206.5K
- Awards on record
- 8
- Top funding agencies
- Department of Veterans Affairs
Awards
36C26025F0084
Completed: Period of performance ended Feb 13, 2025QALSODY BULK
Department of Veterans Affairs
- Obligated
- $43.5K
- Period of performance
- Nov 13, 2024 – Feb 13, 2025
36C26024F0506
Completed: Period of performance ended Sep 30, 2024QALSODY 6.7MG/ML INJ,SOLN
Department of Veterans Affairs
- Obligated
- $32.6K
- Period of performance
- Jul 20, 2024 – Sep 30, 2024
36C26124N0873
Completed: Period of performance ended Sep 19, 2024EMERGENCY PHARMACEUTICAL - QUALSODY (TOFERSEN)
Department of Veterans Affairs
- Obligated
- $21.7K
- Period of performance
- Sep 4, 2024 – Sep 19, 2024
36C26124N0750
Completed: Period of performance ended Aug 2, 2024QALSODY (TOFERSEN) 6.7MG SOLN (2 VIALS) NDC: 64406-0109-01
Department of Veterans Affairs
- Obligated
- $21.7K
- Period of performance
- Jul 2, 2024 – Aug 2, 2024
36C26024F0379
Completed: Period of performance ended Jun 1, 2024QALSODY
Department of Veterans Affairs
- Obligated
- $43.5K
- Period of performance
- Apr 24, 2024 – Jun 1, 2024
36C26124N0658
Completed: Period of performance ended May 16, 2024QALSODY (TOFERSEN) - EMERGENCY PHARMACY
Department of Veterans Affairs
- Obligated
- $21.7K
- Period of performance
- May 16, 2024 – May 16, 2024
36C26124N0621
Completed: Period of performance ended May 16, 2024QALSODY (TOFERSEN) - EMERGENCY PHARMACY
Department of Veterans Affairs
- Obligated
- $10.9K
- Period of performance
- May 1, 2024 – May 16, 2024
36C26124N0494
Completed: Period of performance ended Apr 13, 2024QALSODY (TOFERSEN) 6.7MG SOLN NDC: 64406-0109-01
Department of Veterans Affairs
- Obligated
- $10.9K
- Period of performance
- Mar 13, 2024 – Apr 13, 2024
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
36C26025F0084 under 36F79718D0566 QALSODY BULK | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $43.5K | Nov 13, 2024 – Feb 13, 2025 | Completed: Period of performance ended Feb 13, 2025 |
36C26024F0506 under 36F79718D0566 QALSODY 6.7MG/ML INJ,SOLN | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $32.6K | Jul 20, 2024 – Sep 30, 2024 | Completed: Period of performance ended Sep 30, 2024 |
36C26124N0873 under 36F79718D0566 EMERGENCY PHARMACEUTICAL - QUALSODY (TOFERSEN) | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $21.7K | Sep 4, 2024 – Sep 19, 2024 | Completed: Period of performance ended Sep 19, 2024 |
36C26124N0750 under 36F79718D0566 QALSODY (TOFERSEN) 6.7MG SOLN (2 VIALS) NDC: 64406-0109-01 | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $21.7K | Jul 2, 2024 – Aug 2, 2024 | Completed: Period of performance ended Aug 2, 2024 |
36C26024F0379 under 36F79718D0566 QALSODY | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $43.5K | Apr 24, 2024 – Jun 1, 2024 | Completed: Period of performance ended Jun 1, 2024 |
36C26124N0658 under 36F79718D0566 QALSODY (TOFERSEN) - EMERGENCY PHARMACY | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $21.7K | May 16, 2024 – May 16, 2024 | Completed: Period of performance ended May 16, 2024 |
36C26124N0621 under 36F79718D0566 QALSODY (TOFERSEN) - EMERGENCY PHARMACY | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $10.9K | May 1, 2024 – May 16, 2024 | Completed: Period of performance ended May 16, 2024 |
36C26124N0494 under 36F79718D0566 QALSODY (TOFERSEN) 6.7MG SOLN NDC: 64406-0109-01 | Department of Veterans Affairs | 325412 · 6505DRUGS AND BIOLOGICALS | $10.9K | Mar 13, 2024 – Apr 13, 2024 | Completed: Period of performance ended Apr 13, 2024 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
No sub-award reports yet
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · sync date not recorded · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
No SBIR/STTR awards on record
Source: SBIR.gov award records (opens in a new tab) · sync date not recorded
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 325412Pharmaceutical Preparation ManufacturingPrimary
SAM.gov does not report this entity as small under any listed NAICS code.
Socio-economic status
No socio-economic certifications reported in SAM.gov.
Product & service codes (PSC)
- 6505DRUGS AND BIOLOGICALS
PSC names from the Acquisition.gov PSC Manual (opens in a new tab) (April 2025 edition), checked Nov 12, 2026.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with BIOGEN U.S. CORPORATION?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
